Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
Beteiligte Einrichtungen
Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
ISSN | 0022-1899 |
DOIs | |
Status | Veröffentlicht - 31.08.2023 |
Anmerkungen des Dekanats
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PubMed | 36857443 |
---|